Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U1WP
|
|||
| Former ID |
DIB005096
|
|||
| Drug Name |
MV-CEA
|
|||
| Synonyms |
Measles virus derivative producing cea; Carcinoembryonic antigen-expressing measles virus (cancer), NCI; Mv-cea (ovarian and peritoneal cavity cancer), NCI
Click to Show/Hide
|
|||
| Indication | Glioblastoma multiforme [ICD-11: 2A00.0; ICD-9: 191] | Phase 1 | [1] | |
| Company |
National Cancer Institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | Modulator | [1] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1;70(3):875-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.